Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Elizabeth Ditty"'
Autor:
Jeremy R. Duvall, Raghida A. Bukhalid, Naniye M. Cetinbas, Kalli C. Catcott, Kelly Lancaster, Keith W. Bentley, Suzanna Clark, Susan Clardy, Scott D. Collins, Anouk Dirksen, Elizabeth Ditty, Bingfan Du, Eugene W. Kelleher, Travis Monnell, Marina Protopopova, Caitlin Routhier, Cheri Stevenson, Elena Ter-Ovanesyan, Joshua D. Thomas, Alex Uttard, Jason Wang, Phonphimon Wongthida, Ling Xu, Annika Yau, Jeffrey Zurita, Dorin Toader, Marc Damelin, Timothy B. Lowinger
Publikováno v:
Cancer Research. 82:3503-3503
We present here a novel therapeutic agent, XMT-2056, that results in robust anti-tumor activity mediated by an immune response through targeted delivery of a STING agonist to the tumor microenvironment. By leveraging an antibody-drug conjugate (ADC)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0104b7acc0fcee8f20a6655acfc9a034
https://doi.org/10.1158/1538-7445.am2022-3503
https://doi.org/10.1158/1538-7445.am2022-3503
Autor:
Kalli C. Catcott, Susan Clardy, Jack Sadowsky, Rebecca K. Rowntree, Naniye Malli Centibas, Ling Xu, Andy Polson, Kenneth Avocetien, Tyler Carter, Mark Nazzaro, Dokyong \\'DK\\' Kim, Thomas H. Pillow, Neelie Zacharias, Cong Wu, Jeffrey Zurita, Elizabeth Ditty, Stephen Bradley, Alex Uttard, Bingfan Du, William S. Sawyer, Doug Leipold, Gail Lewis Phillips, LiuLiang Qin, Kelly Slocum, Geoffrey Del Rosario, Ginny Li, Shang-Fan Yu, David Lee, Radha Iyengar, Marc Damelin, Dorin Toader, Timothy B. Lowinger
Publikováno v:
Molecular Cancer Therapeutics. 20:P167-P167
Key defining attributes of an antibody-drug conjugate (ADC) include the choice of targeting antibody, linker, and the drug-to-antibody ratio (DAR). The choice of DAR, within the constraints of acceptable physicochemical properties for the given platf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::935b7e76f6213d4a5e30f27ebae7723c
https://doi.org/10.1158/1535-7163.targ-21-p167
https://doi.org/10.1158/1535-7163.targ-21-p167
Autor:
Kelly Slocum, Rebecca Mosher, Jeffrey Zurita, Kenneth Avocetien, Joshua D. Thomas, Timothy B. Lowinger, Kalli C. Catcott, Susan M. Clardy, Marc Damelin, Jeremy R. Duvall, Marina Protopopova, Naniye Malli Cetinbas, Scott D. Collins, Ling Xu, Keith W. Bentley, Brian D. Jones, Elena Ter-Ovanesyan, Eugene W. Kelleher, Timothy Eitas, Raghida A. Bukhalid, Dorin Toader, Liping Yang, Travis Monnell, Elizabeth Ditty, LiuLiang Qin, Winnie Lee, Pamela Shaw, Phonphimon Wongthida, Stephen Bradley
Publikováno v:
Cancer Research. 81:1738-1738
STING pathway agonism has emerged as a potential therapeutic mechanism to stimulate an innate anti-tumor immune response. However, the systemic administration of a free STING agonist may be limited by toxicity, and broad biodistribution may not be id
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6dd4080a98b5a36ec4e0e10f0f535b90
https://doi.org/10.1158/1538-7445.am2021-1738
https://doi.org/10.1158/1538-7445.am2021-1738
Autor:
Scott D. Collins, Kelly Slocum, Jason K. Wang, Dorin Toader, Ling Xu, Elizabeth Ditty, Chen-Ni Chin, Anouk Dirksen, Marc Damelin, Steven Vonderfecht, Rebecca Mosher, Dokyong Kim, Jeffrey Zurita, Susan M. Clardy, Kenneth Avocetien, Ronald Eydelloth, Timothy B. Lowinger, LiuLiang Qin, Bingfan Du, Steven Bradley, Shawn P. Fessler, Phonphimon Wongthida, Alex Uttard, Elena Ter-Ovanesyen
Publikováno v:
Cancer Research. 81:907-907
XMT-1660 is a novel Dolasynthen-based antibody drug conjugate carrying a DolaLock payload with controlled bystander effect and targeting B7-H4, a tumor antigen that is broadly expressed on the cell surface in breast, ovarian and endometrial cancers.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d2807e2ea7c8be1c11fb15f3c7dc8f0
https://doi.org/10.1158/1538-7445.am2021-907
https://doi.org/10.1158/1538-7445.am2021-907
Autor:
Shawn Fessler, Anouk Dirksen, Scott D. Collins, Ling Xu, Winnie Lee, Jason Wang, Ron Eydelloth, Elena Ter-Ovanesyen, Jeffrey Zurita, Elizabeth Ditty, Barrett Nehilla, Susan Clardy, Tyler Carter, Kenneth Avocetien, Mark Nazzaro, Nam Le, Kalli C. Catcott, Alex Uttard, Bingfan Du, Chen-Ni Chin, Rebecca Mosher, Kelly Slocum, Liuliang Qin, David Lee, Dorin Toader, Marc Damelin, Timothy B. Lowinger
Publikováno v:
Cancer Research. 80:2894-2894
The Dolasynthen platform incorporates the highly potent anti-mitotic agent auristatin F-HPA (AF-HPA), with its associated DolaLock mechanism of controlled bystander effect, and enables the synthesis of antibody-drug conjugates (ADCs) with precise con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d13a6293b254a8a5ceb2133d5934aa3
https://doi.org/10.1158/1538-7445.am2020-2894
https://doi.org/10.1158/1538-7445.am2020-2894